scholarly journals Treatment outcome of postoperative radiotherapy for squamous cell carcinoma of the head and neck

2017 ◽  
Vol 4 (1) ◽  
pp. 127
Author(s):  
H. U. Ghori ◽  
M. Sohaib ◽  
Vivek Tiwari ◽  
Manish Ahirwar
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Early Stage ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Disease Status ◽  
Patient Characteristics ◽  
Neck Tumors ◽  
Modality Approach

<p class="abstract"><strong>Background:</strong> Though early stage malignancy of head and neck can be cured by surgery or radiotherapy, cure of patients with locally advanced disease continues to pose a therapeutic challenge. Loco regional failure is the major cause of death in head and neck cancer. As the cure of locally advance head and neck cancer is less than expectation, a combined modality approach is generally used in these type of patients. The combination of surgery, radiotherapy and chemotherapy can improve outcome in locally advance head and neck cancer.</p><p class="abstract"><strong>Methods:</strong> This observational study reviewed cancer patients reported in our hospital with the following inclusion criteria: primary head and neck cancer, treatment with radical surgery, and multiple nodal metastases. The prescribed dose of postoperative radiotherapy was 60–66 Gy. Patient characteristics, treatment parameters and clinical outcome were recorded.  </p><p class="abstract"><strong>Results:</strong> The primary end point was overall survival, and the secondary endpoint was disease status.</p><p><strong>Conclusions:</strong> Concurrent postoperative administration of chemotherapy and radiotherapy is a way to intensify treatment for resectable high-risk head and neck tumors.</p>

scholarly journals Postoperative Radiotherapy in Head and Neck Cancer

2010 ◽  
Vol 2 (1) ◽  
pp. 43-51
Author(s):  
Vedang Murthy ◽  
Sayan Kundu ◽  
Tanweer Shahid ◽  
Ashwini Budrukkar ◽  
Tejpal Gupta ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Targeted Therapy ◽  
Head And Neck ◽  
Neck Cancer ◽  
Early Stage ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Head And Neck Cancers ◽  
Advanced Head ◽  
Locoregional Failure

Abstract Though early stage head and neck cancers can be cured either by surgery or radiation, patients with locally advanced disease continues to pose a therapeutic challenge. Locoregional failure is the major cause of death in head and neck cancers. As the outcome of locally advanced head and neck cancer is less than promising, a combined modality approach is generally undertaken in this group of patients. The combination of surgery, radiation and more recently, chemotherapy and targeted therapy can improve outcomes in locally advanced head and neck cancer patients. This overview discusses the rationale and role of postoperative radiotherapy (PORT) in advanced head and neck cancers, the radiotherapy technique in brief and methods of enhancing the efficacy of postoperative RT by altering the fractionation schedules and adding chemotherapy and targeted therapy.

scholarly journals Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone

2021 ◽  
Author(s):  
Teresa Magnes ◽  
Sandro M. Wagner ◽  
Thomas Melchardt ◽  
Lukas Weiss ◽  
Gabriel Rinnerthaler ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Registry ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Patient Characteristics ◽  
High Dose ◽  
Radiotherapy Alone

Summary Background The addition of cisplatin or cetuximab to radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) has significantly improved the outcome. While the superiority of cisplatin over cetuximab in combination with radiotherapy has been shown in a definitive setting, we set out to compare postoperative chemoradiotherapy with cisplatin to radioimmunotherapy with cetuximab and radiotherapy alone within the Austrian head and neck cancer registry of the Working Group on Pharmaceutical Tumor Treatment (AGMT) study group. Material and methods In the AGMT head and neck cancer registry, data of 557 patients with SCCHN from five Austrian cancer centers were prospectively collected between 2012 and 2017. Of these patients 120 received postoperative chemoradiotherapy with cisplatin, 26 patients received postoperative radioimmunotherapy with cetuximab and 56 patients were treated with adjuvant radiotherapy only. Patient characteristics, stage of disease, details on treatment as well as survival were analyzed by a chart-based review. Results In patients treated with postoperative radiotherapy the addition of cisplatin significantly improved progression-free survival (PFS) and overall survival (OS) compared to cetuximab (PFS 84.2 months vs. 17.0 months, p = 0.04, OS not reached vs. 46.0 months, p = 0.02) and PFS compared to radiotherapy alone (PFS 84.2 months vs. 28.5 months, p < 0.01). Patients treated with cetuximab were significantly older and had a worse performance score than patients receiving cisplatin or radiotherapy alone. Conclusion This study confirmed the importance of multimodal treatment concepts in patients with locally advanced SCCHN. Postoperative cetuximab might be an option in patients not eligible for high-dose cisplatin but cisplatin should remain the standard of care.

Postoperative radiotherapy for advanced head and neck cancer in patients with cardiac pacemakers

2013 ◽  
Vol 13 (1) ◽  
pp. 115-118 ◽  
Author(s):  
Federico L. Ampil ◽  
Cherie-Ann Nathan ◽  
Ghali Ghali ◽  
David Kim
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Clinical Situation ◽  
Cardiac Events ◽  
Cardiac Pacemakers ◽  
Postoperative Irradiation ◽  
Precautionary Measures

AbstractThe clinical situation of coexisting significant cardiac arrhythmias complicating head and neck cancer (HNC) is uncommon, accounting for <11% of comorbid illnesses present in this particular cohort of individuals. Little is documented about the outcomes of these people with cardiac pacemakers (CP) when surgery combined with postoperative radiotherapy is rendered. The authors report two cases wherein full-course postoperative irradiation was administered without any patient mishap. Appropriately indicated adjuvant radiotherapy for locally advanced HNC can be conducted safely and effectively in patients with CPs. Implementation of essential precautionary measures is encouraged to avoid any serious, unwanted cardiac events.

Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer

1989 ◽  
Vol 75 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Giovanni Franchin ◽  
Antonino De Paoli ◽  
Carlo Gobitti ◽  
Giovanni Boz ◽  
Emilio Minatel ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Survival Rate ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Resection Margins ◽  
Combined Modality Treatment ◽  
Advanced Head

This retrospective study was conducted on 255 consecutive patients with locally advanced squamous-cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, treated at the Radiotherapy Department of Pordenone General Hospital between January 1975 and December 1985. All patients underwent radical surgery followed, after an interval ranging from 10 days to 2.9 months, by radiotherapy given either through a 6 MeV linear accelerator or a cobalt-60 unit. Field extension and dose delivered were comparable in relation to stage and involvement of the surgical resection margins. The aims of the study were to evaluate the survival rate and to analyze the clinical parameters which can influence the disease-free survival. The adjusted overall 5-year survival rate was 71%; stage, performance status at diagnosis, and site of the primary tumor were significant factors in determining patient prognosis, whereas Infiltration of resection margins was not significant in determining locoregional control of disease. Seventy-five patients relapsed and 67 died of cancer-related diseases whereas death in 52 patients was not related to the head and neck cancer. The combined modality treatment consisting of surgery followed by radiotherapy was well tolerated and proved to be effective in the treatment of locally advanced head and neck tumors.

scholarly journals Postoperative radiotherapy with weekly cisplatin in locally advanced head and neck cancer

2017 ◽  
Vol 28 ◽  
pp. v383-v384
Author(s):  
A. Hervás ◽  
J. Domínguez ◽  
D. Candini ◽  
M. Martín ◽  
C. Vallejo
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Advanced Head ◽  
Weekly Cisplatin

Micro-RNA Profiling as a Predictor of Clinical Outcomes for Head and Neck Cancer Patients

2017 ◽  
Vol 23 (32) ◽  
pp. 4729-4744 ◽  
Author(s):  
Tatyana Isayeva ◽  
Margaret Brandwein-Gensler ◽  
Maheshika Somarathna ◽  
Lakisha D. Moore-Smith ◽  
Timmy Lee
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Advanced Disease ◽  
Early Stage ◽  
Locally Advanced ◽  
Micro Rna ◽  
Treatment Modalities ◽  
Survival Outcomes ◽  
Recurrence Rates

Head and neck cancer is one of the leading malignancies worldwide. Due to the lack of symptoms in the early stage of the disease, about two thirds of patients present with locally advanced disease at the time of diagnosis. Even with significantly improved survival rates over the past two decades due to advanced imaging and treatment modalities, locoregional recurrence rates in patients with advanced disease ranges from 16% to 35%. Alternative therapeutic targets are being developed to improve survival outcomes. MicroRNAs (miRNA or miRs) are a family of small non-coding RNA species that have been demonstrated to regulate all cellular, physiological and developmental processes. Recently, there has been an exponential increase in the number of studies suggesting that miRNA is involved in regulating tumor metastasis, chemoresistance, radioresistance and survival outcomes. MiRNA candidates have been identified as potential prognostic biomarkers to diagnose cancer stages and progression, as well as to monitor follow-up treatment. In this review, we will discuss the miRNA profile in each stage of head and neck patients' therapy, with an emphasis on its application to clinical outcome prognosis.

Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer

2004 ◽  
Vol 70 (2) ◽  
pp. 183-188 ◽  
Author(s):  
Abderrahim Zouhair ◽  
David Azria ◽  
Philippe Pasche ◽  
Roger Stupp ◽  
Julia Chevalier ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Advanced Head ◽  
Concomitant Boost

scholarly journals UNRESECTABLE HEAD AND NECK CARCINOMAS

2007 ◽  
Vol 14 (01) ◽  
pp. 111-119
Author(s):  
AHMAD IJAZ MASUD ◽  
QAISER MAHMOOD ◽  
NASREEN SIDDIQUE
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Early Stage ◽  
Locally Advanced ◽  
Head And Neck Carcinoma ◽  
Ulcer Bleeding ◽  
Early Stage Disease ◽  
Female Ratio ◽  
Neck Carcinoma

Introduction: Cancers of the head and neck are estimated to be the most prevalent cancers in the world. Data from various cancer centers of Pakistan reveal that epithelial head and neck cancer is one of the most frequent cancers varying from 12 to 25% of the total new patients seenannually. Objectives: To see the effect of concomitant chemo-radiotherapy on the survival of patient, to assess the toxicity of different treatment arms and the effect of age, sex and bulk or tumour on survival and compare the literature. Setting: Radiotherapy Department, Nishtar Hospital, Multan. Duration: 2 years. Material and Methods: Sample Size: 200 patients. Results: Out of 130 patients, 83 were males and theremaining 47 were females. The male to female ratio being 1.8:1. The mean age of the patients included in the study was 52 years, range being 22-80 years. The patients of head and neck cancer in the trial had different sites of involvement. In the trial the patients presented with various symptoms such as pain, swelling, ulcer, bleeding, dysphagia, dyspnea, hoarseness of voice and nasal obstruction etc. No patient had early stage disease. All the patients in the trial had the experience of nausea and vomiting, it was more marked in patients having radiotherapy; either alone or in concomitant with chemotherapy. The patients having concomitant chemo-radiotherapy i.e. group-C also had diarrhoea as a side effect. The effect on the liver function test was more pronounced in patients of group-A. The renal function was seen to alter more in patients receiving chemotherapy with cisplatin, whether as induction or as a concomitant to radiotherapy. Conclusion: Concomitant chemo-radiotherapy in locally advanced, unresectable head and neck carcinoma is statistically superior to induction chemotherapy followed by radiotherapy and the standard radiotherapy alone.

Sign in / Sign up

Export Citation Format

Share Document